Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema

Blood (2020) 135 (14): 1101–1110.

https://doi.org/10.1182/blood.2019002300

Published: 2020

Includes: Supplemental data

Journal Articles

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Gabrielle Sonigo, Maxime Battistella, Marie Beylot-Barry, Saskia Ingen-Housz-Oro, Nathalie Franck, Stéphane Barete, Serge Boulinguez, Olivier Dereure, Nathalie Bonnet, Gérard Socié, Pauline Brice, Olivia Boccara, Christine Bodemer, Henri Adamski, Michel D’Incan, Nicolas Ortonne, Sylvie Fraitag, Florence Brunet-Possenti, Stephane Dalle, Felipe Suarez, Ambroise Marçais, François Skowron, Dima Haidar, Eve Maubec, Gerome Bohelay, Liliane Laroche, Antoine Mahé, Elodie Birckel, Jean-David Bouaziz, Isabelle Brocheriou, Romain Dubois, Sarah Faiz, Jehane Fadlallah, Caroline Ram-Wolff, Agnes Carlotti, Guido Bens, Brigitte Balme, Beatrice Vergier, Sara Laurent-Roussel, Lydia Deschamps, Olivier Carpentier, Philippe Moguelet, Genevieve Herve, François Comoz, François Le Gall, Guy Leverger, Antoine Finon, Olivier Augereau, Claire Bléchet, Remy Kerdraon, Laurence Lamant, Emilie Tournier, Frédéric Franck, Valérie Costes-Martineau, Vanessa Szablewski, Sebastien Taix, Isabelle Beschet, Frédéric Guerin, Fernando E. Sepulveda, Martine Bagot, Genevieve de Saint Basile, David Michonneau, Adele de Masson

Blood (2020) 135 (13): 1058–1061.

https://doi.org/10.1182/blood.2019003811

Published: 2020

Includes: Supplemental data

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Blood (2018) 132 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2018-99-118204

Published: 2018

Journal Articles

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Blood (2018) 132 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2018-99-119566

Published: 2018

Journal Articles

Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma

Edith Chevret, Laetitia Andrique, Martina Prochazkova-Carlotti, Jacky Ferrer, David Cappellen, Elodie Laharanne, Yamina Idrissi, Anna Boettiger, Wafa Sahraoui, Florian Ruiz, Anne Pham-Ledard, Beatrice Vergier, Francis Belloc, Pierre Dubus, Marie Beylot-Barry, Jean-Philippe Merlio

Blood (2014) 123 (12): 1850–1859.

https://doi.org/10.1182/blood-2013-05-500686

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Fiona Child, MD, Pablo Ortiz Romero, Prof., Rute Alvarez, MD, Martine Bagot, Rudolf Stadler, MD, Michael Weichenthal, MD, Rosario Alves, MD, Maria Grazia Bernengo, Prof., Marie Beylot-Barry, Prof., Richard Cowan, Larisa J. Geskin, MD, Amparo Pérez Ferriols, Peter Hellemans, MD, Yusri Elsayed, MD, PhD, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3676.

https://doi.org/10.1182/blood.V120.21.3676.3676

Published: 2012

Journal Articles

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Brad Pohlman, Ranjana Advani, MD, Madeleine Duvic, MD, Kenneth B. Hymes, MD, Tanin Intragumtornchai, MD, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, MD, Dina Ben-Yehuda, Marie beylot-Barry, Uwe Hillen, Jan Fagerberg, Francine M Foss

Blood (2009) 114 (22): 920.

https://doi.org/10.1182/blood.V114.22.920.920

Published: 2009

Journal Articles

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

Melanie G. Cornejo, Michael G. Kharas, Miriam B. Werneck, Séverine Le Bras, Sandra A. Moore, Brian Ball, Marie Beylot-Barry, Scott J. Rodig, Jon C. Aster, Benjamin H. Lee, Harvey Cantor, Jean-Philippe Merlio, D. Gary Gilliland, Thomas Mercher

Blood (2009) 113 (12): 2746–2754.

https://doi.org/10.1182/blood-2008-06-164368

Published: 2009

Includes: Supplemental data

Journal Articles

Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas

Blood (2004) 103 (10): 3662–3668.

https://doi.org/10.1182/blood-2003-08-2726

Published: 2004

Journal Articles

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases

Blood (2000) 95 (7): 2212–2218.

https://doi.org/10.1182/blood.V95.7.2212

Published: 2000

NARROW

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only